Skip to content
x.com· @ · X·· 2026-04-23Score60

zoldonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.

Body

#AACR26 highlights #CommunityOnc:

1. #CM77T: PeriOP/PostOP Nivo in NSCLC

2. #TRUST: ROS1 1L NSCLC

3. RAS Inhibitor
- Zoldonrasib in 2L and beyond NSCLC

4. RAS Inhibitor in Panc Ca
- Daraxonrasib monotherapy in 1 L
- Daraxonrasib + chemo in 1L

#OncTwitter #MedX

1/6 https://t.co/UmaT0r69jO

Heat 93 · 69 likes · 1 reply · 23 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by 药名 daraxonrasib
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org